The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed. This study is a real world study, aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitor(ICI) combined with chemotherapy, and to explore the correlation and predictive value of each single biomarker, so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment.
Study Type
OBSERVATIONAL
Enrollment
56
Shuhua Han
Nanjing, Jiangsu, China
RECRUITINGProgression-free survival(PFS)in days
the time between the time a patient with tumor disease begins treatment and the time when disease progression is observed or death from any cause occurs.
Time frame: From date of enrollment until the date of first documented progression, assessed up to 2 years.
ctDNA in concentration
The best predictive value of ctDNA concentration change threshold and the best collection time.
Time frame: The First treatment (month 1), the second treatment (month 2) and the time of progression (assessed up to 2 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.